ClinicalTrials.gg
CompletedNCT04871997Updated Oct 21, 2022

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

An observational study in NSCLC, sponsored by Qian Chu. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-21.

Sponsored by Qian Chu · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
373
Ages
18 Years and older
Sex
All
01

Study summary

A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer:This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.

Read the detailed description

A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer:This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.This study is a non-interventional, prospective, observational, real-world case study and all registered data are collected from real clinical practice cases. Adult patients diagnosed as advanced non-small cell lung cancer and treated with anlotinib were included. At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm.The primary endpoint was progression-free survival (PFS) and the secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.If the last patient reaches the main evaluation index or has intolerable toxic reaction, the observation will be finished, and the first one will prevail.Through Electronic Data Capture System (EDC) system, electronic case report form (eCRF) is used to replace paper-based case report form to collect and manage clinical trial data.

02

Conditions studied

  • NSCLC

Keywords

  • NSCLC
  • anlotinib
  • PFS
03

In context

Lead sponsor

Qian Chu is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed as advanced non-small cell lung cancer and treated with anlotinib were included,with no gender restriction

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥18 years old, no gender limit.
  2. Diagnosed as advanced non-small cell lung cancer.
  3. At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm.
  4. Doctors evaluate the benefits of receiving Anlotinib treatment.
  5. The patient voluntarily joins the project and signs the . If any of the above items is "No", the patient is not suitable for this study.

Exclusion criteria

Exclusion Criteria:

  1. Those who have been confirmed to be allergic to anlotinib and/or its .
  2. Patients with anlotinib .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
373 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. progression-free survival (PFS)

    the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse

    Time frame: 2019.7-2022.7

Secondary outcomes

  1. overall survival (OS)

    the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.

    Time frame: 2019.7-2022.7

  2. objective response rate (ORR)

    the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment

    Time frame: 2019.7-2022.7

  3. disease control rate (DCR)

    the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.

    Time frame: 2019.7-2022.7

07

Study locations

1 site
  • Hubei province
    Wuhan, Hubei 430030, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Jul 2022, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2021
First posted
May 4, 2021
StartActual
Jul 12, 2019
Primary completionActual
Jul 16, 2022
CompletionActual
Jul 16, 2022
Last update
Oct 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04871997
Lead sponsor
Qian Chu
Responsible party
Qian Chu (Professor, Tongji Hospital) — Sponsor-investigator
First posted
May 4, 2021
Start date
Jul 12, 2019
Primary completion
Jul 16, 2022
Completion
Jul 16, 2022
Last update
Oct 21, 2022

Study contacts

Qian Chu
principal investigator · Tongji Hospital
Tienan Yi
principal investigator · Xiangyang Central Hospital
Youhong Dong
principal investigator · Xiangyang No.1 People's Hospital
Ruizhi Ran
principal investigator · The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Yang Fu
principal investigator · Xiangyang Hospital of Traditional Chinese Medicine
Guangqiao Qu
principal investigator · The Central Hospital of Xiao Gan
Jun Li
principal investigator · The Central Hospital of Xiao Gan
Yinping Li
principal investigator · The Central Hospital of Xiao Gan
Yanhua Xu
principal investigator · Jingzhou Central Hospital
Xinhua Xu
principal investigator · Yichang Central People's Hospital
Zhiguo Luo
principal investigator · Affiliated Taihe Hospital of Hubei University of Medicine
Fengjun Cao
principal investigator · Shiyan Renmin Hospital
Li Kuang
principal investigator · Dongfeng Hospital Affiliated to Hubei Medical College
Yifa Yin
principal investigator · The Second People's Hospital of Yichang
Guiming Chen
principal investigator · JingMen NO.2 People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion